The reduction in PMP22 protein expression is a promising approach for potential CMT1A therapy, as demonstrated by the shRNA knockdown of Pmp22 in a rodent model of CMT1A, which resulted in increased myelination and the prevention of motor and sensory impairment [12]. This evidence concerns the gene PMP22 and Charcot-Marie-Tooth disease type 1A.